Evaluation of smoking-specific and generic quality of life measures in current and former smokers in Germany and the United States

Table 5 Correlations among measures, German and US current and former smokers

Sample and measure	Scoring^a	Current smoking status^b	CPD	Smoking-specific symptoms	Smoking impact	PCS	MCS
German Sample (N = 179)
Biomarkers
4-ABP		0.720**	0.817**	0.439**	0.171*	0.013	0.099
CEMA		0.681**	0.773**	0.375**	0.179*	−0.006	0.064
4-ABP-Hb		0.712**	0.826**	0.538**	0.189*	−0.062	0.137
CEVal		0.659**	0.793**	0.500**	0.221**	−0.054	−0.046
Survey Measures
Smoking Symptoms	−	0.476**	0.537**
Smoking Impact	−	0.354**	0.251**	0.372**
SF-36 PCS	+	0.060	0.005	−0.091	−0.099
SF-36 MCS	+	0.104	0.107	−0.154*	−0.298**	−0.041
US Sample (N = 259)
Survey Measures
Smoking Symptoms	−	0.491**	0.527**
Smoking Impact	−	0.465**	0.364**	0.550**
SF-36 PCS	+	−0.163**	−0.207**	−0.162**	−0.097
SF-36 MCS	+	−0.098	−0.154*	−0.418**	−0.371**	-0.068

*p < .05, **p < .01
^aNegative (−) indicates higher score equals worse health; positive (+) indicates higher score equals better health
^b1 = current smoker; 0 = former smoker
Note: 4-ABP = 4-aminobiphenyl; CEMA = 2-cyanoethylmercapturic acid; 4-ABP-Hb = 4-aminobiphenyl hemoglobin adduct; CEVal = 2-cyanoethylvaline hemoglobin

ISSN: 1477-7525